Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

19 Aug 2013 16:02

RNS Number : 0303M
Skyepharma PLC
19 August 2013
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Skyepharma PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

On market transfer between direct and indirect funds

3. Full name of person(s) subject to thenotification obligation: iii

Aviva plc & its subsidiaries

4. Full name of shareholder(s)  (if different from 3.):iv

Registered Holder:

 

Chase (GA Group) Nominees Limited 637,000

 

Chase Nominees Limited 98,418

 

Vidacos Nominees Limited 807,000

* denotes direct interest

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

16 August 2013

6. Date on which issuer notified:

19 August 2013

7. Threshold(s) that is/are crossed orreached: vi, vii

3% to

 

 

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary Shares GBP1GB00B3BFNB64

 

 

 

1,542,418

 

1,542,418

1,542,418

Nil Held

1,542,418

Nil Held

3.34%

 

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

 

 

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

Nominal

Delta

 

 

 

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,542,418

3.34%

 

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:-

 

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

 

 

 

 

 

Proxy Voting:

10. Name of the proxy holder:

See Section 4

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

 

13. Additional information:

Aviva have notified a change in the nature of their holdings from direct to indirect holdings, no change in percentage of shares held.

 

14. Contact name:

J Murphy

15. Contact telephone number:

020 7881 1172

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEKLFFXVFBBBF
Date   Source Headline
25th Sep 20122:31 pmRNSflutiform Launched in the UK
25th Sep 20128:00 amRNSTotal Voting Rights
25th Sep 20127:43 amRNSSubmission of New Drug Application in Japan
24th Sep 20122:53 pmRNSBond Proposals Approved
21st Sep 201210:02 amRNSflutiform Launched in Germany
18th Sep 201210:55 amRNSDirector/PDMR Shareholding
6th Sep 201210:26 amRNSHolding(s) in Company
4th Sep 20127:19 amRNSProduct Launch
23rd Aug 20127:00 amRNSRegulatory Approval
23rd Aug 20127:00 amRNSBondholder Agreement
23rd Aug 20127:00 amRNSHalf Yearly Report
8th Aug 20123:06 pmRNSHolding(s) in Company
7th Aug 20123:51 pmRNSDirector/PDMR Shareholding
27th Jul 20127:00 amRNSRAYOS (Lodotra) receives approval in U.S
17th Jul 20127:00 amRNSflutiform Receives Regulatory Approval in Germany
6th Jul 20129:25 amRNSDirector/PDMR Shareholding
3rd Jul 201211:26 amRNSRegulatory Approval
22nd Jun 20127:00 amRNSResearch Update
14th Jun 20129:56 amRNSDirector Declaration
7th Jun 20125:25 pmRNSDirector/PDMR Shareholding
16th May 20121:51 pmRNSResult of AGM
16th May 20127:00 amRNSInterim Management Statement
11th May 201210:35 amRNSDirector/PDMR Shareholding
27th Apr 20125:49 pmRNSHolding(s) in Company
27th Apr 201211:16 amRNSAnnual Information Update
23rd Apr 20123:39 pmRNSHolding(s) in Company
20th Apr 20122:23 pmRNSFlutiform Positive Outcome
20th Apr 20127:40 amRNSExparel $10m milestone payment
13th Apr 201210:29 amRNSAnnual Financial Report
11th Apr 20127:00 amRNSRespivert Contract
5th Apr 20123:36 pmRNSDirector/PDMR Shareholding
22nd Mar 20127:00 amRNSFinal Results
15th Mar 20124:44 pmRNSDirector/PDMR Shareholding
12th Mar 20127:00 amRNSNotice of Results
8th Feb 20129:00 amRNSNEW ORAL DEVELOPMENT ORGANISATION
3rd Feb 20125:28 pmRNSDirector/PDMR Shareholding
31st Jan 20128:30 amRNSDirectorate Change
10th Jan 201212:32 pmRNSDirector/PDMR Shareholding
10th Jan 20129:21 amRNSReorganisation of Swiss Operations
23rd Dec 20117:00 amRNSProduct Update
12th Dec 20115:09 pmRNSDirector Declaration
12th Dec 20113:39 pmRNSDirector/PDMR Shareholding
29th Nov 201112:16 pmRNSRegulatory Application
14th Nov 20117:00 amRNSInterim Management Statement
4th Nov 20114:15 pmRNSDirector/PDMR Shareholding
31st Oct 20112:41 pmRNSUS FDA approval of NDA for Exparel
21st Oct 20114:40 pmRNSSecond Price Monitoring Extn
21st Oct 20114:35 pmRNSPrice Monitoring Extension
18th Oct 20117:00 amRNSUPDATE ON FLUTIFORMT EUROPE
11th Oct 201110:26 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.